Global veterinary cat diet market index seen rising 68% by 2035

IndexBox projects the global veterinary diet cat food market index to rise from 100 in 2025 to 168 by 2035, a 68% increase and a 5.3% compound annual growth rate over 2026-2035.

This companion-cat forecast comes from a modeled commercial study, not a clinical trial; it gives no animal sample size or diet-to-diet efficacy comparison and does not rely on survey opinion as its core evidence. Historical analysis typically covers 2012-2025, with scenarios through 2035; absolute volumes and revenues remain undisclosed.

What is driving demand?

Veterinary diet cat food means specialized, nutritionally complete food sold under veterinary prescription or recommendation. Entering 2026 with broader demand, disciplined procurement and more diversified regional supply, the category remains high-margin and professionally gated, with premium therapeutic and emerging over-the-counter tiers.

Growth drivers include pet humanization, higher healthcare spending, aging cats, rising veterinary diagnosis rates, and chronic kidney disease, urinary disorders, obesity and diabetes. Royal Canin, part of Mars Petcare, is identified as dominant; broader insurance and easier dosing should support adherence.

Veterinarians control the initial choice; palatability, convenience and perceived efficacy drive repeat purchase at home. Brand trust rests on recommendation authority and benefit messaging for urinary health, weight management and renal support, while innovation targets nutrition science, freshness, palatability and dosing.

Private labels and alternative channels are the largest disruptive force. Grocery, drugstores and pure-play e-commerce can win value-seeking owners with mild or chronic conditions through lower prices and retailer credibility.

Which channels control access?

• Veterinary clinics and hospitals: The primary therapeutic gatekeeper, with veterinarians shaping first prescriptions and product selection. The stable-to-growing channel should benefit from nutrition in routine protocols, insurance, in-clinic dispensing and telemedicine follow-up. Watch visit rates, insurance penetration and clinics with dedicated nutrition-counseling staff.
• Pet specialty retail: A growing channel for Petco Health and Wellness, PetSmart, Royal Canin, Hill's and Blue Buffalo. Loyalty programs, trained staff, consultations and linked online/offline replenishment aid growth, but therapeutic authorization limits nonclinic assortment. Watch foot traffic, loyalty penetration and health-positioned SKU share.
• E-commerce and subscriptions: The fastest-growing channel and an expected share gainer, led by Chewy, Amazon, Petco, Royal Canin and Hill's. Autoship, authorization verification, personalized recommendations and telemedicine support adherence; specialized or cold-chain packaging can constrain some products. Watch e-commerce penetration, subscription attach rates and conversion rates.
• Mass retail and grocery: Growing but price-sensitive, with Purina Pro Plan Veterinary Diets, Blue Buffalo, Diamond, WellPet and private labels serving owners seeking affordable support without a prescription. Over-the-counter claim limits restrict them largely to health support. Watch private-label penetration, store traffic and health-positioned SKU share.
• Breeders, shelters and pharmacies: A niche but stable segment supported by specialized needs and professional networks. Growth may come from breeder and shelter networks and pharmacy-based nutrition. Watch shelter intake and adoption, breeder-network size and pharmacy penetration; Royal Canin, Hill's, Purina Pro Plan, Virbac and Dechra are listed.

How will pricing and geography change?

Premium prices should remain firm because scientific substantiation and brand equity support them; value-tier margins face pressure as private labels gain share. Baseline growth is front-loaded as veterinary visits recover and insurance rises, then moderates as alternatives capture mild-condition demand.

Key risks are slower veterinary visits, tighter therapeutic-claim rules and faster private-label entry. Upside comes from evidence linking nutrition to disease management, wider insurance, and palatability or dosing innovations that improve long-term compliance.

• Asia-Pacific is the fastest-growing region, driven by urbanization, rising ownership and veterinary infrastructure; growth starts among urban, affluent owners and imported portfolios before local production scales. Watch visits, insurance and e-commerce adoption.
• North America remains largest by value, with stable growth from high veterinary-care standards, insurance and pet humanization. Watch visits and private-label penetration. Europe is mature, with moderate growth, stringent standards, high spending, insurance in key countries and rising e-commerce; watch regulation and premiumization.
• Latin America grows from a smaller base; the Middle East and Africa has emerging potential. Both start with urban, affluent cohorts and imports, while veterinary infrastructure and price sensitivity constrain demand. Watch urbanization, ownership and infrastructure.

Who controls the category?

IndexBox catalogs 23 companies. US participants include Mars (Royal Canin/Iams), Nestlé Purina, Hill's, General Mills (Blue Buffalo), Diamond, WellPet, J.M. Smucker (Rachael Ray Nutrish), Spectrum Brands/Energizer (United Pet Group), Cargill and Manna Pro. Hill's is identified as an early therapeutic-diet pioneer.

Other participants are Virbac, Dechra, Farmina, Heristo, Affinity, CJ CheilJedang, Nisshin, Unicharm, Total Alimentos, Lupus Alimentos, Scheele & Co., Butcher's Pet Care and Partner in Pet Food.

Across the list, businesses span therapeutic diets, animal health, distribution, wet food, ingredients and private-label production. Farmina offers Vet Life; General Mills has BLUE Natural Veterinary Diet; Dechra owns renal-diet brands; Cargill supplies ingredients; Scheele distributes in Europe; and Partner co-manufactures for retailers.

What changes at the exam table?

The report points toward nutritional management embedded in chronic-care protocols, dedicated counseling, in-clinic dispensing and follow-up addressing palatability and dosing. Visit rates, insurance uptake and clinics with nutrition staff are practical demand indicators.

The study provides no clinical efficacy evidence, so it cannot establish that any named diet improves renal, urinary, weight or diabetic outcomes; its findings describe commercial adoption, not treatment recommendations.

Food-animal implications: None assessed; the category excludes non-feline products. Public-health implications: None assessed within this feline-focused commercial study.

Regulatory status: The report mentions veterinary authorization, claim substantiation and possible tightening, but cites no FDA CVM, EMA or USDA approval, authorization or enforcement action for any named diet. Company-list inclusion establishes no regulatory status.

How strong is the evidence?

IndexBox triangulates category reconstruction, company disclosures, retailer pages, assortment checks, packaging and claims analysis, public prices, trade data, regulatory guidance and route-to-market evidence rather than relying chiefly on survey opinion.

It separates chronic-disease, postoperative, life-stage and allergy value pools. Its core category excludes over-the-counter health food, general wellness food, treats, raw or homemade diets, non-feline products, pharmaceuticals, devices and insurance.

Through 2035, the test is whether subscriptions, wider insurance and integrated clinical nutrition can offset private-label entry without weakening veterinary recommendation.